Literature DB >> 30017935

TRAF6 mediates high glucose-induced endothelial dysfunction.

Rong Liu1, Hong Shen1, Tao Wang2, Jian Ma1, Minjie Yuan1, Jing Huang3, Meng Wei4, Fang Liu5.   

Abstract

To investigate the role of tumor necrosis factor-associated factor 6 (TRAF6) in high glucose-induced endothelial cell dysfunction. Human aortic endothelial cells (HAECs) were cultured in high glucose medium, and TRAF6 expression was assayed by quantitative real-time Polymerase Chain Reaction (PCR) and western blotting. The effect of TRAF6 on in vitro endothelial cell viability, apoptosis, migration, and endothelial-monocyte adhesion was investigated by gene knockdown. The expression of TRAF6 and related adhesion molecules was assayed in a mouse streptozotocin-induced type I diabetes model. The signaling pathways associated with TRAF6 effects on endothelial cells were investigated in high glucose HAEC cultures. Culture of HAECs in high glucose medium significantly increased TRAF6 mRNA and protein expression in a time dependent manner. High glucose markedly reduced HAEC viability, apoptosis, and migration, and these effects was significantly reversed by TRAF6 knockdown. High glucose significantly increased intercellular adhesion of THP-1 monocytic cells and HAECs via upregulation of ICAM-1 and VCAM-1 expression, and TRAF6 knockdown attenuated the effect on THP-1 cell adhesion. TRAF6, ICAM-1, and VCAM-1 expression were increased in aorta tissue of mice with streptozotocin-induced diabetes. The free radical scavenger N-acetyl-L-cysteine attenuated TRAF6 expression in HAECs cultured in high glucose medium, and TRAF6 knockdown inhibited high glucose-induced IκB-α degradation and JNK phosphorylation. TRAF6 mediated high glucose-induced endothelial dysfunction via NF-κB- and AP-1-dependent signaling. Targeting TRAF6 may delay progression of vascular diseases during diabetes mellitus and atherosclerosis.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Diabetes; Endothelial dysfunction; High glucose; TRAF6

Mesh:

Substances:

Year:  2018        PMID: 30017935     DOI: 10.1016/j.yexcr.2018.07.014

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

Review 1.  Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective.

Authors:  Ampadu O Jackson; Ganiyu A Rahman; Shiyin Long
Journal:  Mol Cell Biochem       Date:  2021-04-03       Impact factor: 3.396

2.  Syzygium aqueum (Burm.f.) Alston Prevents Streptozotocin-Induced Pancreatic Beta Cells Damage via the TLR-4 Signaling Pathway.

Authors:  Mona F Mahmoud; Shimaa Abdelaal; Heba Osama Mohammed; Assem M El-Shazly; Rachid Daoud; Mohamed A O Abdelfattah; Mansour Sobeh
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

3.  Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells.

Authors:  Katarina Tripska; Ivone Cristina Igreja Sá; Martina Vasinova; Matej Vicen; Radim Havelek; Samira Eissazadeh; Zuzana Svobodova; Barbora Vitverova; Charles Theuer; Carmelo Bernabeu; Petr Nachtigal
Journal:  Front Med (Lausanne)       Date:  2022-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.